Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

et of estimated distributor discounts, government-mandated discounts and rebates, and estimated product returns.  Any future revenues are dependent on market acceptance of PIXUVRI, the reimbursement decisions made by governmental authorities in each country where PIXUVRI is available for sale and other factors. 

Loss from operations for the second quarter of 2013 was $17.9 million, compared to $49.4 million for the same period in 2012.  For the first six months of 2013, loss from operations was $36.3 million compared to $67.5 million for the same period in 2012. The amount recorded for the three and six months ended June 30, 2012 included a $29.1 million expense for acquired in-process research and development related to the acquisition of pacritinib from S*BIO Pte Ltd.  Non-cash, share-based compensation expense for the second quarter and first six months of 2013 was $2.0 million and $4.4 million, respectively, compared to $3.1 million and $5.1 million for the same periods in 2012.

The net loss for the second quarter of 2013 was $18.0 million, or ($0.17) per share, compared to $58.6 million, or ($1.38) per share, for the same period in 2012. For the first six months of 2013, net loss was $37.4 million, or ($0.35) per share, compared to $76.0 million, or ($1.83), per share for the same period in 2012.

As of June 30, 2013, CTI's cash and cash equivalents totaled $28.6 million.

Financial Guidance for 2013CTI reaffirms prior financial guidance that, for 2013, loss from operations excluding non-cash, share-based compensation expense, which is a non-GAAP measure, is expected to be approximately $60 to $65 million.  Year-to-date for the six month period ended June 30, 2013, loss from operations, excluding non-cash share-based compensation expense, which is a non-GAAP measure, was $31.9 million.  For more information regarding CTI's use of these non-GAAP measures and a reconciliation of non-GAAP los
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  The law firm McElroy, Deutsch, Mulvaney ... will serve as host for "Show Me the ... of Healthcare Reform," a one-day conference scheduled for ... reimbursement, compliance and enforcement in a marketplace re-shaped ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... ANGELES and LEIPZIG, Germany ... today announced that it has entered into an ... the development of antibody-based imaging agents to image ... "Our collaboration with Novotectid expands ImaginAb,s capability to precisely ... immune-oncology and autoimmune disease areas. The ability to ...
(Date:9/17/2014)...   GS1 US has published a ... to support the 2013 Drug Supply Chain Security ... in the pharmaceutical supply chain. The document, titled ... Supply Chain Business Processes to Support the Drug ... in collaboration with GS1 Healthcare US®, a GS1 ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... Results Further Validate Lipidomic-Based Therapeutics as an Emerging Area ... ... DIEGO, Sept. 4 Lpath, Inc. (OTC Bulletin,Board: LPTN), the ... in several murine models of human cancer,and AMD with Lpathomab(TM), ...
... HistoRx AQUA(R)-based assays to evaluate, clinical utility of protein ... ... -, NEW HAVEN, Conn., Sept. 4 HistoRx, Inc., ... the Radiation,Therapy Oncology Group (RTOG), a National Cancer Institute-funded clinical,cooperative ...
Cached Medicine Technology:Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 2Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 3HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3
(Date:9/17/2014)... of wine leads to an explosion of flavours in your ... nanosensor that can mimic what happens in your mouth when ... sensation of dryness in the wine. , When wine growers ... number of processes to bring out the desired flavour in ... important part of the taste is known in wine terminology ...
(Date:9/17/2014)... Francisco, CA (PRWEB) September 17, 2014 ... at http://www.marijuanastock.net , recently launched a “Video” ... the different cannabis companies in the marijuana industry ... video section, a website visitor is given access ... videos relevant to marijuana-related businesses and the issues ...
(Date:9/17/2014)... FL (PRWEB) September 17, 2014 Fresh ... is pleased to announce its support of The Silver ... seniors understanding of the many benefits of medical marijuana. ... be the first medical marijuana dispensary and ... which is raising funds to launch a statewide radio ...
(Date:9/17/2014)... September 17, 2014 NetDimensions (AIM: NETD; ... learning management systems, announces the opening of the 2014 ... IL. , "We are very excited to meet up ... tremendous interest in Next Steps from our clients and ... community really is. We look forward to some very ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Altec Products, ... solutions, announced today their Gold Sponsorship of the 2014 ... 2014. The annual conference will take place in Dallas, ... – 23 and is organized and hosted by the ... non-profit organization comprised of members from more than 900 ...
Breaking Medicine News(10 mins):Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:Florida Buds Supports Silver Tour 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 2Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 3
... genetic disease that causes deafness and dumbness has hit a ... victims belong to Gujjar community. // ,Health and Medical ... that at least 72 cases of the disease have surfaced ... New born babies are also affected by the disease" ...
... the brain of mice were augmented, conditions similar to ... was reported by researchers from Stanford University Medical Centre ... in the treatment of this disease in humans. According ... a drug along with cannabis-like chemicals resulted in a ...
... genetic disease, genetics researchers have identified a novel biological ... development, potentially in cases of mental retardation and autism. ... two genes that contribute to Cornelia deLange syndrome (CdLS), ... in 10,000 children. The disease varies from milder to ...
... by x-ray crystallography. The bundle contains eight copies of ... like and unlike colors, respectively. ,Researchers ... found in natural proteins, discovering that they can form ... protein. Their findings could help scientists design drugs that ...
... According to one of the major findings of a ... less than children who sleep less, and they //are ... years later. The results of this new study were ... Child Development. ,Conducted by researchers at ...
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
Cached Medicine News:Health News:Gene Found for Rare Disorder May Reveal New Pathway in Mental Retardation 2Health News:Man-Made Proteins Could Be More Useful Than Real Ones 2Health News:Man-Made Proteins Could Be More Useful Than Real Ones 3Health News:Childhood Obesity Linked With Sleep 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: